Mark R Gilbert Selected Research

Temozolomide (Temodar)

12/2021	Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model.
1/2021	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
1/2021	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.
7/2020	TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma.
5/2020	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
12/2019	Progress in rare central nervous system tumors.
1/2019	Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
1/2019	MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
1/2018	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
1/2018	Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark R Gilbert Research Topics

Disease

124	Neoplasms (Cancer) 04/2022 - 08/2002
109	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 08/2002
87	Glioma (Gliomas) 01/2022 - 08/2002
52	Brain Neoplasms (Brain Tumor) 01/2022 - 03/2003
9	Ependymoma 11/2021 - 05/2010
8	Oligodendroglioma 01/2020 - 05/2007
7	Neoplasm Metastasis (Metastasis) 04/2022 - 01/2004
7	Fatigue 01/2021 - 06/2010
7	Astrocytoma (Pilocytic Astrocytoma) 01/2021 - 10/2002
6	Inflammation (Inflammations) 11/2021 - 07/2015
6	Meningioma (Meningiomas) 08/2021 - 01/2010
5	Disease Progression 01/2021 - 04/2008
5	Necrosis 10/2020 - 07/2003
5	Hypoxia (Hypoxemia) 01/2020 - 05/2015
4	Neurologic Manifestations (Neurological Manifestations) 01/2020 - 01/2004
3	Lymphoma (Lymphomas) 08/2021 - 10/2011
3	Neutropenia 01/2021 - 11/2010
3	Fistula 07/2020 - 04/2012
3	Breast Neoplasms (Breast Cancer) 05/2020 - 08/2002
3	Carcinogenesis 01/2020 - 05/2017
3	Edema (Dropsy) 11/2018 - 12/2007
3	Seizures (Absence Seizure) 01/2016 - 12/2007
3	Gliosarcoma 05/2015 - 12/2012
3	Hypersensitivity (Allergy) 03/2011 - 05/2008
3	Meningitis 09/2009 - 01/2003
2	Genomic Instability 04/2022 - 10/2010
2	Diarrhea 01/2021 - 10/2010
2	Chordoma 01/2021 - 01/2018
2	Hypertension (High Blood Pressure) 01/2020 - 02/2014

Drug/Important Bio-Agent (IBA)

44	Temozolomide (Temodar)FDA LinkGeneric 12/2021 - 10/2002
22	Bevacizumab (Avastin)FDA Link 01/2021 - 09/2007
18	Biomarkers (Surrogate Marker)IBA 12/2021 - 08/2002
16	Pharmaceutical PreparationsIBA 01/2022 - 01/2006
12	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 06/2021 - 02/2013
12	ErbB Receptors (EGF Receptor)IBA 01/2021 - 10/2005
11	EnzymesIBA 01/2021 - 08/2003
11	Anticonvulsants (Antiepileptic Drugs)IBA 03/2016 - 08/2003
10	Biological ProductsIBA 01/2022 - 07/2005
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2002
9	Vincristine (Oncovin)FDA LinkGeneric 10/2020 - 09/2007
9	Lomustine (CCNU)FDA Link 10/2020 - 09/2007
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2017 - 09/2009
8	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 07/2005
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 11/2005
7	Immune Checkpoint InhibitorsIBA 01/2021 - 07/2015
7	Procarbazine (Matulane)FDA Link 10/2020 - 09/2007
7	Alkylating AgentsIBA 12/2019 - 10/2002
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 08/2003
6	VaccinesIBA 03/2021 - 07/2015
5	LigandsIBA 03/2021 - 10/2019
5	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 12/2007
5	MethyltransferasesIBA 01/2021 - 07/2005
5	LB100IBA 06/2020 - 01/2018
5	Thalidomide (Thalomid)FDA Link 02/2015 - 02/2007
4	RNA (Ribonucleic Acid)IBA 04/2022 - 08/2002
4	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 06/2020 - 01/2018
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 10/2011
4	Monoclonal AntibodiesIBA 01/2017 - 09/2007
3	AntigensIBA 01/2021 - 01/2018
3	alpha-hydroxyglutarateIBA 01/2021 - 12/2018
3	Protons (Proton)IBA 01/2021 - 06/2013
3	Lapatinib (GW572016)FDA Link 01/2021 - 05/2015
3	Peptides (Polypeptides)IBA 07/2020 - 11/2010
3	epidermal growth factor receptor VIIIIBA 06/2020 - 11/2010
3	Phosphotransferases (Kinase)IBA 01/2020 - 02/2006
3	GuanineIBA 01/2020 - 07/2005
3	CytokinesIBA 01/2020 - 07/2015
3	Therapeutic UsesIBA 11/2019 - 01/2016
3	CilengitideIBA 03/2016 - 09/2007
3	Cytotoxins (Cytolysins)IBA 11/2015 - 02/2007
3	Tyrosine Kinase InhibitorsIBA 07/2015 - 09/2007
3	Celecoxib (Celebrex)FDA Link 02/2015 - 11/2010
3	temsirolimus FDA Link 04/2014 - 09/2007
3	Cytostatic AgentsIBA 08/2013 - 12/2002
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2011 - 01/2004
2	Anti-Bacterial Agents (Antibiotics)IBA 04/2022 - 09/2015
2	ElementsIBA 01/2022 - 12/2021
2	Histones (Histone)IBA 11/2021 - 01/2020
2	MannansIBA 03/2021 - 09/2020
2	LipidsIBA 01/2021 - 10/2020
2	GlucocorticoidsIBA 01/2021 - 08/2003
2	ChemokinesIBA 01/2021 - 01/2020
2	Vorinostat FDA Link 10/2020 - 11/2012
2	Glucose (Dextrose)FDA LinkGeneric 06/2020 - 01/2020
2	Glutamine (L-Glutamine)FDA Link 06/2020 - 01/2020
2	Chimeric Antigen ReceptorsIBA 01/2020 - 11/2019
2	Carbonic Anhydrase IXIBA 01/2020 - 11/2019
2	c-Mer Tyrosine KinaseIBA 01/2020 - 10/2018
2	Lipase (Acid Lipase)FDA Link 01/2020 - 01/2019
2	Memantine (Namenda)FDA Link 01/2020 - 01/2019
2	Messenger RNA (mRNA)IBA 01/2020 - 04/2006

Therapy/Procedure

79	Therapeutics 01/2022 - 12/2002
45	Radiotherapy 01/2022 - 10/2002
43	Drug Therapy (Chemotherapy) 12/2021 - 12/2002
20	Immunotherapy 12/2021 - 01/2014
5	Chemoradiotherapy 08/2018 - 09/2007
3	Craniotomy 09/2015 - 06/2014
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2021 - 01/2021
2	Adjuvant Chemoradiotherapy 10/2020 - 09/2007
2	Tracheostomy 07/2020 - 05/2015